.png)
METABOLICA HEALTH INC.
promising first in class treatment for diabetes and obesity
ABOUT US
Development Stage Biotechnology Firm
Metabolica Health Inc. is a development stage biotechnology firm discovering and developing innovative treatments for diabetes and obesity. Collaborating with world-class universities, the company focuses on products of intestinal microbiome metabolism.
​
As a frontrunner in discovering and developing groundbreaking treatments, the company collaborates with prestigious universities worldwide, focusing on identifying and understanding the impact of the microbiome and its metabolic products on human health. Metabolica Health Inc. has a valuable Intellectual property (IP) portfolio, including an issued patent from the United States Patent and Trademark Office (USPTO), underscoring our pioneering approach in the vital health domains of diabetes, obesity, and metabolic disease.
​
Building on this foundation, Metabolica Health Inc. is actively developing compounds aimed at the prevention and treatment of insulin-related conditions, with a special focus on enhancing glucose-stimulated insulin secretion. This forward-thinking approach positions Metabolica Health Inc. as a key player in shaping the future of metabolic health, therapeutic weight-loss and diabetes care. Metabolica Health Inc. is gearing up to list on public exchanges in Canada and the United States by 2024.
"Insulin is not a cure for diabetes; it is a treatment. It enables the diabetic to burn sufficient carbohydrates, so that proteins and fats may be added to the diet in sufficient quantities to provide energy for the economic burdens of life."
Frederick Banting
DISCOVERY RESEARCH
World-renowned Research Institutions
The discovery research behind these advances was conducted at world-renowned research institutions, including Sorbonne University in France, McGill University in Canada, and Kyoto University in Japan. Notably, our patent covers a by-product of the gut microbiome that has shown important potential for improving glycemic homeostasis and enhancing the insulin secretory response to glucose in animal models of diabetes. Excitingly, the experimental treatment also reduces body weight in these same animal models.